WonderBiotics vs Calocurb: Which Fits You?

WonderBiotics vs Calocurb: Microbiome Support or Bitter-Brake Appetite Support?

Calocurb's Amarasate hop extract and WonderBiotics' probiotic blend both target appetite and weight, through completely different systems. Calocurb triggers a short, meal-timed spike in your own GLP-1, CCK, and PYY. WonderBiotics Probiotics for Weight Management works through gut bacteria and a separate metabolic blend, building its case over months. Neither replaces prescription GLP-1 therapy.

What Is Calocurb's "Bitter Brake," and Does It Actually Trigger GLP-1?

Calocurb is a New Zealand supplement built around Amarasate®, a supercritical CO2-extracted hop (Humulus lupulus) compound.¹ It's sold as 125 mg capsules, labeled for up to four capsules a day taken about an hour before meals on an empty stomach, priced at $89.99 for a 90-capsule bottle with roughly 15% off on subscription.²

The physiology behind the "bitter brake" is well-described: bitter compounds activate taste receptors on enteroendocrine cells lining the gut, which respond by releasing appetite-related gut hormones, including GLP-1, CCK, and PYY, similar to what the body releases after eating. Amarasate came out of a New Zealand government-funded research program at the New Zealand Institute for Plant and Food Research, a Crown research institute that later licensed the extract to Calocurb Ltd. The institute still holds a minority stake in the company and a royalty on Amarasate sales.³

Calocurb's own published trials disclose that relationship. The disclosed financial relationship limits the independence of the evidence, and B420, the core strain behind WonderBiotics, carries a similar funding pattern, covered below.

What Is WonderBiotics, and How Is the Microbiome Pathway Different?

WonderBiotics Probiotics for Weight Management takes a different route entirely. Instead of one bitter compound acting on taste receptors before a meal, it combines eight probiotic strains (20 billion CFU total) anchored by Bifidobacterium animalis subsp. lactis 420 (B420), in a proprietary blend with polydextrose. A separate Metabolic Blend adds dihydroberberine and a lemon extract standardized to eriocitrin, branded Eriomin®.⁴

WonderBiotics is taken daily. The best human evidence behind B420 comes from a 6-month trial tracking body composition, and the proposed mechanism runs through gut microbiome and metabolic signaling rather than a taste-receptor hormone spike measured in real time.

Calocurb's trials measure hormone changes within hours of a dose. WonderBiotics' evidence tracks body composition across months. If your question is whether a product measurably raises a satiety hormone within an hour of taking it, only Calocurb's trials have actually tested that in people.

How Strong Is the Evidence Behind Calocurb's Claims?

Four published human trials underpin Calocurb's marketing, and they differ in size, design, and who paid for them.

The core mechanism study is a 2022 crossover trial in 19 healthy-weight men.⁵ On three separate days a week apart, each man took a placebo, an immediate-release 500 mg hop-extract capsule, or a delayed-release version, then ate an all-you-can-eat lunch and afternoon snack. Compared with placebo (5,383 kJ total intake), both active treatments cut intake by roughly 17% (gastric delivery: 4,473 kJ, P=.006; duodenal delivery: 4,439 kJ, P=.004). Duodenal delivery raised post-meal CCK to nearly 600% of each person's own fasting baseline, GLP-1 to about 240%, and PYY to about 180%. Ghrelin, a hormone that drives hunger, also rose before lunch in the active arms, a detail that complicates a simple "less hungry" narrative. A New Zealand government grant funded this trial, not Calocurb directly, though several authors work for the institute that holds a royalty on Amarasate sales.

Another crossover trial tested 30 healthy-weight women (27 completed) across three 24-hour water-only fasts, comparing a high dose (500 mg/day), a low dose (250 mg/day), and placebo.⁶ The high dose significantly reduced hunger and raised fullness and satisfaction ratings (P<.05); both doses cut food and savory cravings. At the re-feed meal, energy intake fell 14.3% at the high dose and 8.1% at the low dose versus placebo, though only the high-dose result was statistically significant. Calocurb Ltd funded this trial directly, and the authors disclosed that their employer holds a minority stake in the company.

An earlier 2019 crossover trial tested 30 lean men on a similar 24-hour water-only fast, comparing a high dose (500 mg) and a low dose (200 mg) of the same hop extract against placebo.¹³ Both doses cut hunger ratings by more than 10% during the last six hours of the fast (P<.05) and blunted the hunger spike that placebo-group participants felt around lunchtime. A Plant & Food Research internal fund, not Calocurb, paid for this one; the authors reported no competing financial interests beyond the institute's licensing and royalty arrangement with Calocurb described above.

The newest and largest study, published in 2026, followed 150 adults (ages 18–45, BMI 25–35) in New Zealand for 24 weeks, with 128 completing.⁷ Both the Calocurb group and the placebo group attended the same monthly dietitian-led sessions on eating and activity; only the Calocurb group added 500 mg/day of hop extract, titrated up over three weeks. Among completers at 24 weeks, the Calocurb group lost more weight (-3.8 kg/-4.3%) than placebo (-0.4 kg/-0.5%), more BIA-estimated fat mass (-4.5 kg vs -0.7 kg), and more BIA-estimated visceral fat (-32.5 cm² vs -9.1 cm²), while BIA-estimated muscle mass held steady in both groups. About 10% of the Calocurb group required sustained dose reduction, most to half the prescribed dose and one participant to a quarter dose, because of diarrhea and/or nausea. Calocurb's marketing frames this as "9x more weight loss than willpower alone," but both arms received the same dietitian coaching, so the meaningful comparison is hop extract plus coaching versus coaching alone, not versus no support at all. Calocurb Ltd funded this trial, and it's the only one of the four measuring real-world weight outcomes over months rather than a single day.

The mechanism claim, that bitter compounds trigger GLP-1, CCK, and PYY release around a meal, rests on physiology confirmed in an independently funded study. The weight-loss claim rests on one company-funded, 24-week trial in a population aged 18–45 (menopause status was not reported) that hasn't yet been independently replicated.

How Strong Is the Evidence Behind WonderBiotics' Formula?

B420's flagship trial randomized 225 adults with overweight or obesity to placebo, fiber alone, B420 alone, or B420 plus fiber for 6 months.⁸ The pre-specified primary analysis, comparing all four arms on DXA-measured change in body fat, was not significant (P=.46). In the pre-defined per-protocol group, B420 combined with fiber lost significantly more fat than placebo (-4.5%, P=.02), but B420 alone did not (-3.0%, P=.28). A secondary analysis run after the trial was unblinded, pooling both B420-containing arms against both non-B420 arms, found a significant difference (-4.0% fat, P=.002; -2.4 cm waist, P=.004). That's a hypothesis-generating result, not a confirmed one. DuPont Nutrition & Health, B420's manufacturer (now part of IFF), funded this trial in full, and several authors were company employees.

The B420 trial never measured hunger, cravings, or gut hormones like GLP-1, CCK, or PYY. Its outcomes were body fat and self-reported food intake, not satiety signaling. WonderBiotics' Metabolic Blend, not the probiotic strains, carries the endogenous-GLP-1 angle, and that rests on a smaller, separate evidence base. Eriomin, the lemon extract in that blend, raised GLP-1 by about 17% within the treatment group over 12 weeks, a change that was also significantly higher than placebo; the same trial's reported drops in the inflammation markers IL-6 and TNF-α were within-group changes only. It's a small crossover trial of adults with elevated blood sugar, a different population and endpoint than weight loss, and it was funded by Eriomin's supplier, Ingredients by Nature, though the authors reported no conflict of interest and stated the sponsor had no role in the trial's design or analysis.⁹ Dihydroberberine's own human trial was a 5-person pharmacokinetic pilot testing absorption, not metabolic effect: it showed better absorption than standard berberine but no significant difference in blood glucose or insulin between doses. NNB Nutrition, which supplied the dihydroberberine and funded the trial, also paid one of the authors as an adviser.¹⁰

WonderBiotics is built around B420 precisely because that strain carries its own randomized trial in this population. The finished eight-strain, 20-billion-CFU blend hasn't been tested as a single product, and no published study has combined B420 with a GLP-1 medication, so the evidence we're pointing to sits at the ingredient level, not yet at the level of the finished formula.

Is Calocurb Really a "Non-Prescription GLP-1 Alternative"?

Calocurb calls itself a "GLP-1 Activator," and mechanistically that holds up: it raises your own GLP-1 for a few hours after a dose. That's a different scale of effect than a prescription GLP-1 receptor agonist, though. Semaglutide stays in your blood for about a week between doses (half-life around 160 hours) at concentrations that keep the GLP-1 receptor engaged around the clock.¹¹ Calocurb's own FAQ describes the effect as lasting several hours per dose, tied to a single meal. Both raise GLP-1 activity; they don't do it at the same intensity or for the same duration, and no trial has compared the two directly. Calocurb's FAQ page tells users to check with their doctor before combining it with a GLP-1 receptor agonist, and it lists inflammatory bowel disease, type 1 diabetes, pregnancy, and breastfeeding as reasons to avoid the product.¹² The same logic applies to adding any new supplement, including WonderBiotics, on top of a GLP-1 prescription: ask your prescriber first.

Which One Fits Your Situation?

If what you need is help getting through a specific meal or a fasting window without white-knuckling it, Calocurb's evidence is built for exactly that: three of its four trials measure acute hunger, cravings, or calorie intake around a meal or a fast. If you're managing weight as a months-long project and want a daily habit that also supports gut health, WonderBiotics Probiotics for Weight Management is built for that timeline instead, pairing eight studied strains with a metabolic blend rather than a single bitter compound.

We anchored WonderBiotics in B420, a probiotic strain with a published randomized controlled trial for weight management, and paired it with ingredients like Eriomin that carry their own separate human data on endogenous GLP-1 signaling, rather than betting on one compound and one mechanism. WonderBiotics is intended for daily use, whereas Calocurb is taken before selected meals.

Nothing here replaces medical care. If you take a prescription GLP-1 medication, talk with your prescriber before adding any supplement, including WonderBiotics Probiotics for Weight Management or Calocurb. If you're immunocompromised, have inflammatory bowel disease, or are pregnant or breastfeeding, check with a clinician before starting either category of product.

The Bottom Line

Calocurb and WonderBiotics solve different problems on different timelines, and the evidence quality behind each specific claim varies within each brand. Calocurb's acute appetite data comes from physiology trials, independently funded in some cases, while its weight-loss claim rests on one newer, company-funded study awaiting outside replication. WonderBiotics' B420 evidence is modest and industry-funded, and its GLP-1-related claim sits in a separate part of the formula, not in the probiotic strains themselves. Neither is a stand-in for prescription therapy, and no published trial has tested them together or against each other.

References

1. Amarasate: The Active Ingredient in Calocurb — Calocurb Wholesale.
2. Calocurb GLP-1 Activator product page — Calocurb.
3. Amarasate: The Active Ingredient in Calocurb — Calocurb Wholesale (Plant & Food Research licensing/royalty background).
4. WonderBiotics Probiotics for Weight Management — WonderBiotics.
5. Walker EG, et al. An extract of hops (Humulus lupulus L.) modulates gut peptide hormone secretion and reduces energy intake in healthy-weight men: a randomized, crossover clinical trial. Am J Clin Nutr. 2022;115(3):925-940. PMID 35102364.
6. Walker EG, et al. Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting. Obesity Pillars. 2024. PMC11279280.
7. Amarasate 24-week randomized, double-blind, placebo-controlled trial ("C4 trial") on body weight, fat mass, visceral fat, and muscle mass. Obesity Pillars. 2026;19:100299. DOI 10.1016/j.obpill.2026.100299.
8. Stenman LK, et al. Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial. EBioMedicine. 2016;13:190-200. PMID 27810310 / PMC5264483.
9. Cesar TB, Ramos FMM, Ribeiro CB. Nutraceutical Eriocitrin (Eriomin®) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial. J Med Food. 2022;25(11):1050-1058. PMID 35796695.
10. Moon JM, et al. Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients. 2022;14(1):124. PMID 35010998.
11. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol. 2024;15:1431292. PMC11304055.
12. Calocurb FAQs — Calocurb.
13. Walker EG, Lo KR, Tham S, Pahl MC, Lomiwes DD, Cooney JM, Wohlers MW, Gopal PK. New Zealand Bitter Hops Extract Reduces Hunger During a 24 h Water Only Fasting Period. Nutrients. 2019;11(11):2754. PMC6893682.